Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 1014 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 11/1/1997


1.		Phase II/III Pilot Treatment of Pediatric Non-B, Non-T ALL in First Marrow Relapse (SIMAL #8): Intensive Re-Induction and Reconsolidation Chemotherapy with Subsequent Myeloablative Chemoradiotherapy and Rescue with Either Allogeneic or In Vitro-Purged Autologous Marrow (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21 at relapse				NCI				POG-9410 POG-SIMAL-8

Last Modified: 3/1/1998


2.		Phase II/III Randomized Study of Fluorouracil/Leucovorin with vs without Oxaliplatin for Inoperable Metastatic Colorectal Cancer (Summary Last Modified 03/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 75								FRE-DEB95-OXA-01 EU-96023


3.		Master Protocol to Compare MTX/5-FU vs CACP/5-FU vs Phase II Agent for Squamous Cell Cancer of the Head and Neck (Summary last modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				SWOG-8223/24/25 SWOG-8224, SWOG-8225


4.		Phase II/III Chemotherapy and Hormone Therapy with ADR/VCR/DBD/PRED Followed by TMX/FXM/BLEO/HMM/MTX-CF for Metastatic Stage III/IV or Recurrent Breast Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 65								WCCC-CO-7711R NCI-D80-048-183


5.		Phase II/III Evaluation of Intraoperative Radiotherapy and Adjuvant Chemotherapy with CAM (CTX/ADR/MTX) for Nonmetastatic Soft Tissue Retroperitoneal Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				10 to 65				NCI				NCI-80-C-45 NCI-SB-S9, NCI-T83-1103N, T83-1103


6.		Phase II/III Adjuvant ADR/CTX Followed by High-Dose MTX vs ADR/CTX Alone, with Radiotherapy in Selected Cases, for Histologic Grade II/III Soft Tissue Sarcoma of an Extremity

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified								NCI-82-C-100


7.		Phase II/III Combination Chemotherapy with AMSA/AZC or AMSA/VP-16 for Acute Nonlymphocytic Leukemia Refractory to Standard Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								NCI-D82-013-686


8.		Phase II-III Chemotherapy with High-Dose Methotrexate and Adriamycin plus Radiotherapy for Primary and Metastatic Osteogenic Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				20 and under								CHOP-204


9.		Phase II Chemotherapy with MTX/CF, Aminopterin or M-BACOD plus CTX or BCG Immunotherapy for Advanced non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				25 to 65								DFCI-75116

Last Modified: 9/1/1988


10.		Phase II/III Induction Chemotherapy with CACP/BLEO/MTX/CF vs CACP/5-FU for Stage II/III/IV, Previously Untreated Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 09/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				NCI				DFCI-83084 NCI-T84-0282D, T84-0282

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute